The majority of the analysts states the share is now attractively priced. Currently the company is being followed by 13 analysts. The recommendations for the stock contain no sells, 9 times hold and 4 times buy. The average of the current target prices for the stock equals 92,33 USD. This is at around 26 percent more than the current price of 72,72 USD. The most recent recommendations for the biotech company are from Barclays , Morgan Stanley and Jefferies & Co..
Gilead Sciences 's market capitalization is around 103,41 billion USD.
On Thursday the stock closed at 72,72 USD.
Analist.nl Nieuwsdienst: +31 084-0032-842
Copyright analist.nl B.V.
All rights reserved. Any redistribution, duplication or archiving prohibited. Analist.nl doesn't warrant the accuracy of any News Content provided and shall not be liable for any errors, inaccuracies or for any actions taken in reliance thereon.